Theragen Etex

Theragen Etex operates on two main pillars: manufacturing and sale of prescription and general drugs, and genome sequencing/analysis services, with subsidiaries including Leadpharm (pharmacy distribution), Theragen Healthcare, and Theragen Bio.

The pharmaceutical segment is produced at the Ansan plant in Gyeonggi Province, and in 2024 three products—Nexon Tab, Rosuvastatin Tab, and Pravixen Tab—each surpassed KRW 10bn in annual sales, with four more products expected to join that tier in 2025.

On a standalone basis, company revenue is estimated to have nearly doubled over three years, from KRW 90.2bn in 2022 to roughly KRW 172bn in 2025.

In genomics, the company competes with Macrogen, DNA Link, and LabGenomics in Korea's genome analysis services market, and in September 2024 it was one of two finalists alongside Macrogen for a KRW 50bn sub-project of the national integrated bio big-data initiative.

In direct-to-consumer genetic testing, the company previously launched a healthcare platform through a joint venture, Theragen Health, with Lotte Healthcare, and has also collaborated with LG Household & Health Care on related services.

That said, the pharmaceutical segment's revenue growth—driven by an expanding prescription-drug distribution mix and a broader, smaller-batch supply model—has faced profitability constraints from drug-price regulation and softer domestic consumption.

On the new-drug side, the company holds exposure to the Vactosertib oncology candidate through affiliate MedPacto, though that equity stake is currently classified as held for sale.

In sum, the company combines a relatively stable generic/prescription drug cash flow base with growth optionality in genomics and new-drug assets.

Consolidated revenue rose for four consecutive years, from KRW 193.4bn in 2022 to KRW 221.7bn in 2023, KRW 249.6bn in 2024, and KRW 271.6bn in 2025. Operating profit fluctuated in the KRW 10.3–12.5bn range from 2022 to 2024, then eased slightly to KRW 10.2bn in 2025, while the operating margin held at 3.8%.

The most notable shift was at the net-income line: owners' net income deteriorated sharply to a loss of KRW 41.0bn in 2024 before turning to a profit of KRW 10.6bn in 2025.

Because the 2024 shortfall occurred even as revenue and operating profit grew 12.5% and 8.2% respectively, it suggests one-off items below the operating line—likely related to equity-method losses or valuation/disposal losses tied to affiliates such as MedPacto.

On a quarterly basis, operating profit was negative at KRW -0.5bn in 2025Q2 but recovered to KRW 2.0bn in Q3 and KRW 4.2bn in Q4 of 2025, then continued positive at KRW 1.9bn in 2026Q1 and KRW 2.6bn in 2026Q2.

However, owners' net income for 2026Q1 was still negative at KRW -3.7bn despite the operating profit, underscoring continued volatility below the operating line.

Combined revenue over the most recent four quarters (2025Q3–2026Q2) totaled roughly KRW 275.4bn, exceeding the prior full year, while combined owners' net income over the same span was only about KRW 1.7bn, highlighting a gap between the pace of revenue growth and net-income improvement.

On the balance sheet, the debt ratio rose from 56.4% in 2022 to 81.5% in 2024 before easing to 61.9% in 2025, while operating cash flow fell sharply to KRW 1.8bn in 2024 before recovering to KRW 11.0bn in 2025.

Korea's pharmaceutical industry continues to navigate structural constraints from drug-price regulation and soft domestic consumption by expanding prescription-drug distribution and diversifying product lineups.

In genome analysis services, phased deregulation of direct-to-consumer (DTC) genetic testing has drawn large conglomerates such as Lotte Healthcare, LG Household & Health Care, and Amorepacific into the space through partnerships or joint ventures with specialist firms.

Even so, slow DTC market growth and intensifying competition have made profitability difficult to sustain for genomics service providers as a group.

Against this backdrop, a KRW 50bn sub-project under the national integrated bio big-data initiative that emerged in the second half of 2024 was viewed as a potential turning point for the sector, with Macrogen and Theragen Etex seen as the leading contenders in what shaped up as a two-way race.

Competitively, Theragen Etex sits among Korea's larger genome-analysis service providers alongside Macrogen, DNA Link, and LabGenomics, with large-scale data collection/analysis capacity and consortium-building ability seen as the key variables in winning such contracts.

In pharmaceuticals, a broader, smaller-batch supply model and a growing prescription-drug mix have served as the main levers for defending revenue, but persistent downward pressure on drug prices remains a structural constraint on industry-wide margin expansion.

The company has internally targeted a recovery in annual operating profit to the KRW 12bn range through refined sales strategy and cost-structure review, while also signaling an aim to accelerate its way into the top 30 of Korea's domestic pharmaceutical market through a strengthened product lineup.

The tenure of CEO Park Si-hong, credited with driving revenue expansion since 2023, was reported to be up for reappointment discussion at the March 2026 annual general shareholders' meeting.

On governance, whether largest shareholder Ko Jae-hoon (10.14% stake) expands his management role, including a potential board seat, remains a point to watch.

The planned MedPacto stake sale, decided in November 2024, has seen delays in advisor selection and buyer sourcing, with its book value roughly halved; the company maintains that the process has not been suspended and remains under internal review.

In genomics, the national integrated bio big-data project runs through 2028 as a multi-year initiative, making consortium formation and follow-on contract outcomes a variable that could affect future results.

On the financial side, debt repayment pressure persists, and completion of the MedPacto sale would be expected to improve liquidity, though timing remains uncertain.